Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

491
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
491
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

263
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
263
Depression: Overview01:18

Depression: Overview

491
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
491
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

953
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
953
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

1.6K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.6K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

375
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
375

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metacognitive Belief Profiles Across OCD Symptom Dimensions: A Systematic Review and Clinical Implications for Personalised Treatment.

Journal of clinical medicine·2026
Same author

Digital Assessment of Metacognition Across the Psychosis Continuum: Measures, Validity, and Clinical Integration-A Scoping Review.

Medicina (Kaunas, Lithuania)·2026
Same author

Type A Aortic Dissection: From Diagnosis to Cardiac Rehabilitation.

Journal of clinical medicine·2026
Same author

Mortality Due to Aortic Dissection in Adults With Primary Hypertension: A Nationwide Analysis Over Two Decades.

Clinical cardiology·2026
Same author

Catching the Storm Before It Breaks: Advancing Early Diagnosis and Intervention in Bipolar Disorder.

Life (Basel, Switzerland)·2026
Same author

Multimodality Cardiovascular Imaging in Patients After Coronary Artery Bypass Grafting: Diagnosis and Risk Stratification.

Diagnostics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Oct 27, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.7K

Treating Postpartum Depression: What Do We Know about Brexanolone?

Muneeza Ali1, Alifiya Aamir1, Mufaddal Najmuddin Diwan1

  • 1Department of Internal Medicine, Dow Medical College, Karachi 74200, Pakistan.

Diseases (Basel, Switzerland)
|July 21, 2021
PubMed
Summary

Postpartum depression (PPD) is a serious concern. Brexanolone, a new drug, shows significant effectiveness in reducing PPD symptoms, offering hope for mothers.

Keywords:
brexanoloneeffectivenesspostpartum depressionpregnancysafety

More Related Videos

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.2K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.2K

Related Experiment Videos

Last Updated: Oct 27, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.7K
Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.2K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.2K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Postpartum depression (PPD) affects 12% globally and is a leading cause of pregnancy-related death.
  • The FDA approved brexanolone in 2019, the first drug specifically for PPD treatment.

Purpose of the Study:

  • Review brexanolone's pharmacology.
  • Evaluate clinical data and outcomes for PPD treatment.
  • Assess brexanolone's status as a breakthrough and identify cost barriers.

Main Methods:

  • Analysis of clinical trial data, including safety, tolerability, and efficacy.
  • Primary outcome measured by reduction in Hamilton Rating Scale for Depression (HAM-D) scores.
  • Brexanolone administered via a 60-hour intravenous infusion.

Main Results:

  • All three randomized controlled trials showed statistically significant reductions in HAM-D scores compared to placebo.
  • Brexanolone demonstrated efficacy in treating moderate-to-severe PPD.
  • Sustained effects were evaluated at days 7 and 30 post-treatment.

Conclusions:

  • Brexanolone is an effective treatment for PPD, supported by robust clinical trial data.
  • Further evaluation is needed regarding its 'breakthrough' status and cost-related accessibility.
  • The drug represents a significant advancement in PPD management.